Inactive Instrument

News Lion Biotechnologies Inc OTC Bulletin Board

Equities

LBIO

US53619R1023

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

05-13	Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained	MT
05-13	Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting	05-23	AQ
Iovance Biotherapeutics : 2022 Annual Report	05-22	PU
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	05-20	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	05-17	AQ
Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	05-14	AQ
Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained	05-13	MT
Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating	05-13	MT
Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says	05-10	MT
Iovance Biotherapeutics Shares Fall After Q1 Revenue Misses Estimates	05-10	MT
Iovance Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Iovance Biotherapeutics Q1 Loss Narrows -- Shares Higher After Hours	05-09	MT
Transcript : Iovance Biotherapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Iovance Biotherapeutics: Q1 Earnings Snapshot	05-09	AQ
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Posts Q1 Revenue $715,000	05-09	MT
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates	05-09	AQ
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024	05-01	AQ
Iovance Biotherapeutics to Present at Upcoming Conferences	04-30	AQ
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting	04-24	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - April 19, 2024	04-22	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	04-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lion Biotechnologies Inc OTC Bulletin Board

Equities

LBIO

US53619R1023

Summary

Filters